Page 9 - Session Title News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio April 8, 2021 GMT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 8, 2021-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data inclu...

Message : Required fields -- AFM24 preclinical in vivo data will be presented as a poster -- Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) ) AFM24 have been accepted for e-poster presentation at the American Association for Cancer Research (AA...

Share this article Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the abstract, Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, was selected for an E-Poster Session presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 and will be available on April 10, 2021. Voruciclib is an orally available inhibitor of cyclin-dependent kinase 9 (CDK9...